Last edition
News about "chronic spontaneous urticaria "
Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.
Chronic Spontaneous Urticaria | 09/06/2026 | By News Bureau | 108
Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido
Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.
Chronic Spontaneous Urticaria | 28/04/2026 | By News Bureau | 121
European Commission Approves Dupixent for Young Children with Chronic Spontaneous Urticaria
The European Commission has expanded approval of Dupixent to children aged 2–11 with chronic spontaneous urticaria, offering a targeted treatment for those unresponsive to standard antihistamines.
Chronic Spontaneous Urticaria | 15/04/2026 | By News Bureau | 120
Barzolvolimab Shows Sustained, Off-Treatment Benefits in Chronic Spontaneous Urticaria at AAAAI 2026
Phase II data presented at AAAAI 2026 show barzolvolimab achieved rapid, durable complete responses in chronic spontaneous urticaria, with sustained disease control observed months after treatment discontinuation.
Chronic Spontaneous Urticaria | 12/02/2026 | By News Bureau | 300
Sanofi and Regeneron's Dupixent Receives Positive CHMP Opinion
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Dupixent (dupilumab), jointly developed by Sanofi and Regeneron, for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents in the EU.
Chronic Spontaneous Urticaria | 22/09/2025 | By Dineshwori | 408
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy